Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®)
- Conditions
- Japanese EncephalitisYellow Fever
- Interventions
- Biological: Live attenuated Japanese encephalitis virus; Yellow fever virusBiological: Yellow fever virus; Live attenuated Japanese encephalitis virus
- First Posted Date
- 2009-09-22
- Last Posted Date
- 2012-09-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 108
- Registration Number
- NCT00982137
Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine
- Conditions
- Japanese Encephalitis
- Interventions
- Biological: ChimeriVax™ diluent (Placebo)Biological: Live attenuated Japanese encephalitis virus
- First Posted Date
- 2009-09-22
- Last Posted Date
- 2012-12-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 128
- Registration Number
- NCT00981630
Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes
- First Posted Date
- 2009-09-22
- Last Posted Date
- 2012-03-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 30
- Registration Number
- NCT00981240
- Locations
- 🇺🇸
Sanofi-Aventis Investigational Site Number 840003, Atlanta, Georgia, United States
🇺🇸Sanofi-Aventis Investigational Site Number 840002, New York, New York, United States
🇺🇸Sanofi-Aventis Investigational Site Number 840001, Houston, Texas, United States
24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2009-09-15
- Last Posted Date
- 2016-10-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 319
- Registration Number
- NCT00976937
- Locations
- 🇺🇸
Sanofi-Aventis Investigational Site Number 840004, Medford, Oregon, United States
🇺🇸Sanofi-Aventis Investigational Site Number 840003, Muscle Shoals, Alabama, United States
🇺🇸Sanofi-Aventis Investigational Site Number 840006, Butte, Montana, United States
Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older
- Conditions
- Influenza
- Interventions
- Biological: Trivalent inactivated influenza vaccine High DoseBiological: Trivalent inactivated influenza vaccine
- First Posted Date
- 2009-09-14
- Last Posted Date
- 2012-08-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 9172
- Registration Number
- NCT00976027
24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: PlaceboDevice: Pen auto-injector
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2016-10-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 446
- Registration Number
- NCT00975286
- Locations
- 🇺🇸
Sanofi-Aventis Investigational Site Number 840210, Dallas, Texas, United States
🇺🇸Sanofi-Aventis Investigational Site Number 840211, Baton Rouge, Louisiana, United States
🇺🇸Sanofi-Aventis Investigational Site Number 840230, Hyattsville, Maryland, United States
Safety, Tolerability and Efficacy Study With a Fixed-Dose Combination (FDC) Ketoprofen Plus Omeprazole
- Conditions
- Pain
- Interventions
- Drug: FDC KETOPROFEN+OMEPRAZOLE
- First Posted Date
- 2009-09-03
- Last Posted Date
- 2010-06-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 52
- Registration Number
- NCT00971581
- Locations
- 🇲🇽
Sanofi-Aventis Administrative Office, Col. Coyoacan, Mexico
Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 in Patients With Solid Tumors
- First Posted Date
- 2009-08-31
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 15
- Registration Number
- NCT00968916
- Locations
- 🇯🇵
Sanofi-Aventis Investigational Site Number 392002, Osaka Sayama-Shi, Japan
🇯🇵Sanofi-Aventis Investigational Site Number 392001, Sunto-Gun, Japan
Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Drug: INSULIN GLULISINE (HMR1964)
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2012-07-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 68
- Registration Number
- NCT00964574
- Locations
- 🇧🇾
Sanofi-Aventis Administrative Office, Minsk, Belarus
Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2013-01-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 463
- Registration Number
- NCT00965549
- Locations
- 🇬🇧
Investigational Site Number 826-130, Bristol, United Kingdom
🇬🇧Investigational Site Number 826-149, Barnsley, United Kingdom
🇬🇧Investigational Site Number 826-136, Bradford, United Kingdom